210 related articles for article (PubMed ID: 21393140)
1. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.
Mathur T; Kumar M; Barman TK; Kumar GR; Kalia V; Singhal S; Raj VS; Upadhyay DJ; Das B; Bhatnagar PK
J Antimicrob Chemother; 2011 May; 66(5):1087-95. PubMed ID: 21393140
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Bishara J; Wattad M; Paul M
Clin Infect Dis; 2007 Dec; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
[No Abstract] [Full Text] [Related]
5. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
6. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin therapy for severe Clostridium difficile-associated diarrhea.
Huggan PJ; Murdoch DR
Clin Infect Dis; 2007 Dec; 45(12):1647-8; author reply 1649-51. PubMed ID: 18190330
[No Abstract] [Full Text] [Related]
8. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
9. Clostridium difficile-associated disease treatment response depends on definition of cure.
Lawrence SJ; Dubberke ER; Johnson S; Gerding DN
Clin Infect Dis; 2007 Dec; 45(12):1648; author reply 1649-51. PubMed ID: 18190331
[No Abstract] [Full Text] [Related]
10. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
11. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Louie TJ; Emery J; Krulicki W; Byrne B; Mah M
Antimicrob Agents Chemother; 2009 Jan; 53(1):261-3. PubMed ID: 18955523
[TBL] [Abstract][Full Text] [Related]
12. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile disease and vancomycin--questionable clinical superiority.
Tarchini G
Clin Infect Dis; 2011 Jul; 53(2):212. PubMed ID: 21690637
[No Abstract] [Full Text] [Related]
15. Trial watch: Phase III success for novel Clostridium difficile antibiotic.
Nat Rev Drug Discov; 2010 Apr; 9(4):260. PubMed ID: 20357795
[No Abstract] [Full Text] [Related]
16. Clinical inquiries. What are effective therapies for Clostridium difficile-associated diarrhea?
Ohl ME; Stevermer JJ; Meadows S; Tribuna J; Chek K
J Fam Pract; 2005 Feb; 54(2):176-8. PubMed ID: 15689297
[No Abstract] [Full Text] [Related]
17. Infection of hamsters with historical and epidemic BI types of Clostridium difficile.
Razaq N; Sambol S; Nagaro K; Zukowski W; Cheknis A; Johnson S; Gerding DN
J Infect Dis; 2007 Dec; 196(12):1813-9. PubMed ID: 18190262
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Clostridium difficile in the environment in a rural community in Zimbabwe.
Simango C
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1146-50. PubMed ID: 16698054
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
Bass SN; Bauer SR; Neuner EA; Lam SW
J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates.
Zheng L; Citron DM; Genheimer CW; Sigmon SF; Carman RJ; Lyerly DM; Goldstein EJ
Anaerobe; 2007; 13(3-4):114-20. PubMed ID: 17531516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
